August 12, 2024 07:40 AM EDT

Pfizer touts strength of RSV vaccine in subgroup of younger immunocompromised patients

Katherine Lewin

News Reporter

A few months after touting its RSV vaccine’s effects on younger adults, Pfizer said a sub-study focusing on immunocompromised adults is also positive. The data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer touts strength of RSV vaccine in subgroup of younger immunocompromised patients

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

Novo declares Phase 3 cardiac outcomes trial win for oral GLP-1

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

Starboard takes activist stake in J&J consumer spinout Kenvue

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Pfiz­er touts strength of RSV vac­cine in sub­group of younger im­muno­com­pro­mised pa­tients

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pfizer touts strength of RSV vaccine in subgroup of younger immunocompromised patients